Thompson Davis & Co’s Viking Therapeutics VKTX Stock Holding History

Thompson Davis & Co’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$111K	Sell	6,394 -3,612	-36%	-$43K	0.24%	97
2018 Q2	$95K	Buy	+10,006	New	+$66.6K	0.23%	108

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Thompson Davis & Co's VKTX Position: Q3 2018 in Review

Thompson Davis & Co reduced its Viking Therapeutics (VKTX) stake by 36% in Q3 2018, selling an estimated $43K and leaving 6,394 shares worth $111K. The position accounts for 0.24% of the portfolio, ranked #97.

Thompson Davis & Co first reported a position in VKTX in Q2 2018 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold VKTX as of Q3 2018.

Thompson Davis & Co held 6,394 shares of Viking Therapeutics worth $111K as of Q3 2018.
Thompson Davis & Co sold 3,612 Viking Therapeutics shares in Q3 2018, an estimated $43K.
Viking Therapeutics made up 0.24% of Thompson Davis & Co's portfolio in Q3 2018, its #97 holding.
Thompson Davis & Co first reported a position in Viking Therapeutics in Q2 2018 and has held it in 2 quarters since.
148 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.